Privia Health Group (NASDAQ:PRVA – Get Rating) had its target price reduced by BTIG Research from $45.00 to $40.00 in a research report issued on Monday, The Fly reports. BTIG Research’s price target points to a potential upside of 85.96% from the company’s current price.
Several other research firms have also recently commented on PRVA. Canaccord Genuity Group lowered their target price on Privia Health Group from $50.00 to $43.00 and set a “buy” rating for the company in a research note on Friday, November 11th. Piper Sandler decreased their price objective on Privia Health Group to $42.00 in a research note on Thursday, November 17th. Stifel Nicolaus initiated coverage on Privia Health Group in a research note on Thursday, December 8th. They set a “buy” rating and a $28.00 price objective for the company. UBS Group initiated coverage on Privia Health Group in a research note on Thursday, December 8th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Truist Financial decreased their price objective on Privia Health Group to $41.00 in a research note on Thursday, November 17th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $39.46.
Privia Health Group Stock Performance
NASDAQ PRVA opened at $21.51 on Monday. The stock has a fifty day moving average of $24.62 and a 200-day moving average of $31.84. The stock has a market capitalization of $2.46 billion, a P/E ratio of -59.75 and a beta of 0.67. Privia Health Group has a 52 week low of $17.99 and a 52 week high of $44.64.
Privia Health Group (NASDAQ:PRVA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported $0.01 EPS for the quarter. The company had revenue of $342.90 million during the quarter, compared to analysts’ expectations of $323.66 million. Privia Health Group had a negative return on equity of 6.82% and a negative net margin of 3.02%. Equities research analysts forecast that Privia Health Group will post -0.26 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Privia Health Group news, Director Jeffrey B. Butler sold 39,309 shares of Privia Health Group stock in a transaction dated Tuesday, October 11th. The stock was sold at an average price of $35.09, for a total transaction of $1,379,352.81. Following the transaction, the director now directly owns 3,039,637 shares in the company, valued at $106,660,862.33. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Matthew Shawn Morris sold 27,343 shares of the business’s stock in a transaction dated Thursday, October 13th. The stock was sold at an average price of $34.90, for a total value of $954,270.70. Following the sale, the chief executive officer now directly owns 121,739 shares in the company, valued at $4,248,691.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeffrey B. Butler sold 39,309 shares of the business’s stock in a transaction dated Tuesday, October 11th. The shares were sold at an average price of $35.09, for a total value of $1,379,352.81. Following the completion of the sale, the director now owns 3,039,637 shares in the company, valued at $106,660,862.33. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,873,267 shares of company stock worth $91,138,284. Corporate insiders own 57.60% of the company’s stock.
Institutional Trading of Privia Health Group
A number of institutional investors have recently modified their holdings of PRVA. Assetmark Inc. boosted its position in Privia Health Group by 119.4% during the second quarter. Assetmark Inc. now owns 893 shares of the company’s stock valued at $26,000 after purchasing an additional 486 shares during the last quarter. First Horizon Advisors Inc. boosted its position in Privia Health Group by 4,330.4% during the second quarter. First Horizon Advisors Inc. now owns 1,019 shares of the company’s stock valued at $29,000 after purchasing an additional 996 shares during the last quarter. Signaturefd LLC acquired a new position in Privia Health Group during the third quarter valued at approximately $32,000. Nisa Investment Advisors LLC acquired a new position in Privia Health Group during the second quarter valued at approximately $46,000. Finally, Point72 Hong Kong Ltd acquired a new position in Privia Health Group during the first quarter valued at approximately $47,000. 66.83% of the stock is currently owned by institutional investors.
About Privia Health Group
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Privia Health Group, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Privia Health Group wasn’t on the list.
While Privia Health Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.